Biomarker Commons

Selventa, a biomarker discovery company that enables personalized healthcare through the stratification of patients based on disease-driving mechanisms, recently announced a US patent that relates methods and techniques that facilitate discovery of biomarkers, thus aiding in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

Selventa, a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, today announced that it has formed a strategic scientific alliance with Linguamatics, a software solutions company that provides knowledge extraction through its innovative I2E natural language processing (NLP) text mining platform. The alliance will bring together established analytical capabilities of both companies to efficiently extract complex life science knowledge in a computable, structured, biological expression language (BEL) format that can be used to interpret large-scale experimental data in the context of published literature.